Contemporary outcomes of long-term anticoagulation in COVID-19 patients: a regression matched sensitivity analysis of the national inpatient sample.

IF 1.8 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-07-10 DOI:10.1080/14779072.2023.2234282
Amro Taha, Irisha Badu, Harigopal Sandhyavenu, Varun Victor, Sanchit Duhan, Lalitsiri Atti, Hasham Masood Qureshi, Thatiana Schulze Goni, Bijeta Keisham, Vasantha Sandhya Venu, Harshith Thyagaturu, Karthik Gonuguntla, Waqas Ullah, Himanshu Deshwal, Sudarshan Balla
{"title":"Contemporary outcomes of long-term anticoagulation in COVID-19 patients: a regression matched sensitivity analysis of the national inpatient sample.","authors":"Amro Taha,&nbsp;Irisha Badu,&nbsp;Harigopal Sandhyavenu,&nbsp;Varun Victor,&nbsp;Sanchit Duhan,&nbsp;Lalitsiri Atti,&nbsp;Hasham Masood Qureshi,&nbsp;Thatiana Schulze Goni,&nbsp;Bijeta Keisham,&nbsp;Vasantha Sandhya Venu,&nbsp;Harshith Thyagaturu,&nbsp;Karthik Gonuguntla,&nbsp;Waqas Ullah,&nbsp;Himanshu Deshwal,&nbsp;Sudarshan Balla","doi":"10.1080/14779072.2023.2234282","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The role of oral anticoagulation during the COVID-19 pandemic has been debated widely. We studied the clinical outcomes of COVID-19 hospitalizations in patients who were on long-term anticoagulation.</p><p><strong>Research design and methods: </strong>The Nationwide Inpatient Sample (NIS) database from 2020 was queried to identify COVID-19 patients with and without long-term anticoagulation. Multivariate regression analysis was used to calculate the adjusted odds ratio (aOR) of in-hospital outcomes.</p><p><strong>Results: </strong>Of 1,060,925 primary COVID-19 hospitalizations, 102,560 (9.6%) were on long-term anticoagulation. On adjusted analysis, COVID-19 patients on anticoagulation had significantly lower odds of in-hospital mortality (aOR 0.61, 95% CI 0.58-0.64, <i>P</i> < 0.001), acute myocardial infarction (aOR 0.72, 95% CI 0.63-0.83, <i>P</i> < 0.001), stroke (aOR 0.79, 95% CI 0.66-0.95, <i>P</i> < 0.013), ICU admissions, (aOR 0.53, 95% CI 0.49-0.57, <i>P</i> < 0.001) and higher odds of acute pulmonary embolism (aOR 1.47, 95% CI 1.34-1.61, <i>P</i> < 0.001), acute deep vein thrombosis (aOR 1.17, 95% CI 1.05-1.31, <i>P</i> = 0.005) compared to COVID-19 patients who were not on anticoagulation.</p><p><strong>Conclusions: </strong>Compared to COVID-19 patients not on long-term anticoagulation, we observed lower in-hospital mortality, stroke and acute myocardial infarction in COVID-19 patients on long-term anticoagulation. Prospective studies are needed for optimal anticoagulation strategies in hospitalized patients.</p>","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Cardiovascular Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14779072.2023.2234282","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The role of oral anticoagulation during the COVID-19 pandemic has been debated widely. We studied the clinical outcomes of COVID-19 hospitalizations in patients who were on long-term anticoagulation.

Research design and methods: The Nationwide Inpatient Sample (NIS) database from 2020 was queried to identify COVID-19 patients with and without long-term anticoagulation. Multivariate regression analysis was used to calculate the adjusted odds ratio (aOR) of in-hospital outcomes.

Results: Of 1,060,925 primary COVID-19 hospitalizations, 102,560 (9.6%) were on long-term anticoagulation. On adjusted analysis, COVID-19 patients on anticoagulation had significantly lower odds of in-hospital mortality (aOR 0.61, 95% CI 0.58-0.64, P < 0.001), acute myocardial infarction (aOR 0.72, 95% CI 0.63-0.83, P < 0.001), stroke (aOR 0.79, 95% CI 0.66-0.95, P < 0.013), ICU admissions, (aOR 0.53, 95% CI 0.49-0.57, P < 0.001) and higher odds of acute pulmonary embolism (aOR 1.47, 95% CI 1.34-1.61, P < 0.001), acute deep vein thrombosis (aOR 1.17, 95% CI 1.05-1.31, P = 0.005) compared to COVID-19 patients who were not on anticoagulation.

Conclusions: Compared to COVID-19 patients not on long-term anticoagulation, we observed lower in-hospital mortality, stroke and acute myocardial infarction in COVID-19 patients on long-term anticoagulation. Prospective studies are needed for optimal anticoagulation strategies in hospitalized patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
新冠肺炎患者长期抗凝治疗的当代结果:全国住院患者样本的回归匹配敏感性分析。
背景:口服抗凝在新冠肺炎大流行期间的作用一直备受争议。我们研究了长期接受抗凝治疗的新冠肺炎患者住院的临床结果。研究设计和方法:查询2020年全国住院患者样本(NIS)数据库,以确定新冠肺炎长期抗凝和非抗凝患者。多变量回归分析用于计算住院结果的调整比值比(aOR)。结果:在1060925例原发性新冠肺炎住院患者中,102560例(9.6%)接受了长期抗凝治疗。经调整的分析显示,接受抗凝治疗的新冠肺炎患者住院死亡率的几率显著降低(aOR 0.61,95%CI 0.58-0.64,P P P P P P = 0.005)与未接受抗凝治疗的新冠肺炎患者相比。结论:与未长期抗凝的新冠肺炎患者相比,长期抗凝的新冠肺炎患者住院死亡率、卒中和急性心肌梗死较低。需要对住院患者的最佳抗凝策略进行前瞻性研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Expert Review of Cardiovascular Therapy
Expert Review of Cardiovascular Therapy CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
3.70
自引率
0.00%
发文量
82
期刊介绍: Expert Review of Cardiovascular Therapy (ISSN 1477-9072) provides expert reviews on the clinical applications of new medicines, therapeutic agents and diagnostics in cardiovascular disease. Coverage includes drug therapy, heart disease, vascular disorders, hypertension, cholesterol in cardiovascular disease, heart disease, stroke, heart failure and cardiovascular surgery. The Expert Review format is unique. Each review provides a complete overview of current thinking in a key area of research or clinical practice.
期刊最新文献
Short-term and long-term outcomes of cardiac arrhythmias in patients with cardiogenic shock. Nattokinase as an adjuvant therapeutic strategy for non-communicable diseases: a review of fibrinolytic, antithrombotic, anti-inflammatory, and antioxidant effects. The role of eprosartan in the management of essential hypertension: literature review and expert opinion. What are the early warning signs of myocarditis during the pathway of care? Managing elderly patients with atrial fibrillation and multimorbidity: call for a systematic approach.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1